GlassScriptPhysician profile
David Baghdassarian
NPI 1518151158
$1,568.84
in general payments reported to CMS, 2019-2025
28 companies · $24.55 in 2025
The $24.55 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $19.46 · 2021: $435 · 2022: $461 · 2023: $448 · 2024: $7.74 · 2025: $24.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $342.90 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Applied Medical Resources Corporation | $185.59 | 2021 | |
| Pfizer INC. | $167.24 | 2019-2023 | |
| Gynesonics, INC. | $133.15 | 2022 | |
| Hologic Sales and Service, LLC | $79.85 | 2022-2025 | Thinprep 2000 Processor, Aptima |
| Innovation Technologies INC | $63.69 | 2023 | Irrisept |
| Coopersurgical, INC. | $53.77 | 2019-2021 | |
| Astellas Pharma US INC | $49.95 | 2023 | Veozah |
| Minerva Surgical, INC | $47.71 | 2022 | |
| Millicent US INC | $44.52 | 2022-2023 | Intrarosa |
| Mayne Pharma Commercial LLC | $41.33 | 2023-2024 | |
| Boston Scientific Corporation | $37.56 | 2019-2021 | |
| Coloplast Corp | $36.40 | 2021 | |
| Smith+Nephew, INC. | $35.61 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.69 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $31.82 | 2022-2023 | Slynd |
| Sumitomo Pharma America, INC. | $20.85 | 2023 | Myfembree |
| Abbott Laboratories | $19.77 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $17.44 | 2023 | |
| Daiichi Sankyo INC. | $16.64 | 2021 | |
| Baxter Healthcare | $15.54 | 2023 | Tisseel |
| Novo Nordisk INC | $15.50 | 2023 | Wegovy |
| Becton, Dickinson and Company | $14.66 | 2022 | |
| Acessa Health INC. | $14.22 | 2021 | |
| Organon LLC | $13.54 | 2021 | |
| Mylan Pharmaceuticals INC. | $13.07 | 2019 | |
| Agile Therapeutics, INC. | $12.60 | 2022 | |
| Merck Sharp & Dohme LLC | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Baghdassarian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.